Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue them in partnership. Active Biotech has a global license agreement with NeoTX for the development and commercialization of naptumomab in cancer indications, since 2016. Active Biotech is in an academic partnership with Abramson Cancer institute Philadelphia, USA, for the ongoing development of tasquinimod in multiple myeloma. Recently, we entered into a global patent license agreement with Oncode Institute, acting on behalf of Erasmus MC, for tasquinimod in myelofibrosis.

NeoTX Therapeutics Ltd.

On October 26, 2016 – Active Biotech announced an agreement with NeoTX Therapeutics Ltd., for the development and commercialization of naptumomab estafenatox for cancer immunotherapy.

The licensing agreement grants NeoTX exclusive rights to develop and commercialize naptumomab estafenatox worldwide in cancer indications. The total deal value amounts to USD 71 million and is contingent upon achievement of clinical, regulatory and commercial milestones whereof Active Biotech received USD 250,000 as an initial payment upon signing. In addition, NeoTX will pay Active Biotech progressive, double-digit royalties on its net sales.


Strategic partnerships to secure success

NeoTX Therapeutics Ltd